ImmVirX develops receptor-targeted oncolytic RNA immunotherapies that selectively infect and destroy cancer cells while enhancing systemic anti-tumor immune responses. This approach aims to improve treatment outcomes for prevalent cancers, such as colorectal and ovarian cancer, where patients currently face limited therapeutic options.
Funding
$37.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many prevalent cancers, including colorectal and ovarian cancer, have limited effective therapeutic options, leading to poor patient outcomes. Current treatments often fail to provide durable responses, leaving a significant unmet need for innovative cancer therapies.
Solution
ImmVirX is a clinical-stage oncology company that develops receptor-targeted oncolytic RNA immunotherapies designed to selectively infect and destroy cancer cells while stimulating systemic anti-tumor immune responses. The company's proprietary bio-selection platform enables the development of RNA viruses that target specific receptor proteins highly expressed on cancer cells. These viruses selectively enter, replicate within, and destroy tumor cells, creating beneficial changes in the tumor microenvironment. This approach enhances the effectiveness of existing immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, leading to more durable responses in cancers with high unmet needs. ImmVirX's lead asset, IVX037, is currently in clinical studies, and the company is also advancing a second oncolytic virus asset, IVX055, towards clinical trials.
Target Audience
The primary target audience includes patients with prevalent cancers such as colorectal, gastric, hepatocellular, ovarian, and lung cancer, particularly those with late-stage disease and limited treatment options.
Features
- Receptor-targeted oncolytic RNA viruses for selective cancer cell infection and destruction
- Proprietary bio-selection platform for developing targeted RNA viruses
- Induction of local and systemic anti-tumor immune responses
- Enhanced effectiveness of immune checkpoint inhibitors and CAR-T cell therapies
- IVX037: Lead asset in clinical studies
- IVX055: Second oncolytic virus asset in preclinical development targeting late-stage lung cancer
- Intratumoral administration to liver, lymph node, and abdominal metastases